Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cervical Cancer
Fluorouracil plus radiotherapy did not improve cervix cancer over cisplatin
February 9th, 2006
Protracted venous infusion (PVI) of fluorouracil (FU) plus pelvic radiation did not improve outcome of advanced cervix cancer over weekly cisplatin. "Concurrent chemoradiotherapy is the standard of care for locally advanced cervix cancer; the optimal chemotherapy regimen is not yet defined. This trial was designed to compare the outcome of PVI FU with standard weekly cisplatin and concurrent radiation therapy (RT). Patients with stage IIB, IIIB, and IVA cervical cancer with clinically negative aortic nodes were eligible," scientists in the United States reported. "Pelvic FIT dose was 45 Gy with a parametrial boost to involved sides of 5.4 to 9 Gy,...
Source: Women's Health Weekly (2006-02-09)
|
